<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6334">
  <stage>Registered</stage>
  <submitdate>27/10/2016</submitdate>
  <approvaldate>27/10/2016</approvaldate>
  <nctid>NCT02949011</nctid>
  <trial_identification>
    <studytitle>Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications</studytitle>
    <scientifictitle>A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications</scientifictitle>
    <utrn />
    <trialacronym>CAPSTONE 2</trialacronym>
    <secondaryid>2016-002688-32</secondaryid>
    <secondaryid>1602T0832</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - S-033188
Treatment: drugs - Placebo to S-033188
Treatment: drugs - Oseltamivir
Treatment: drugs - Placebo to Oseltamivir

Experimental: S-033188 - Participants aged = 12 years to 64 years will receive two or four 20-mg S 033188 tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.

Active Comparator: Oseltamivir - Participants aged = 12 years to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four S 033188 placebo tablets on Day 1.

Placebo Comparator: Placebo - Participants aged = 12 years to 64 years will receive two or four S 033188 placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.


Treatment: drugs: S-033188
2-4 X 20-mg tablets taken orally

Treatment: drugs: Placebo to S-033188
2-4 X 20-mg tablets taken orally

Treatment: drugs: Oseltamivir
75-mg capsules taken orally

Treatment: drugs: Placebo to Oseltamivir
Placebo capsules matching oseltamivir 75-mg capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to improvement of symptoms - Time to improvement of symptoms is defined as the time from initiation of study treatment to improvement of influenza symptoms for a duration of at least 21.5 hours (24 hours - 10%).</outcome>
      <timepoint>From Day 1 pretreatment up to Day 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants positive for influenza virus titer and viral RNA at each time point - Defined as the percentage of patients whose virus titer and ribonucleic acid (RNA) load are not less than the lower limit of quantification among those assessed for virus titer and RNA load. RNA load is measured by reverse transcription polymerase chain reaction (RT-PCR).</outcome>
      <timepoint>Days 1, 2, 3, 5 and 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in virus titer at each time point</outcome>
      <timepoint>From Day 1 pretreatment to Days 2, 3, 5, and 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in viral RNA load at each time point</outcome>
      <timepoint>From Day 1 pretreatment to Days 2, 3, 5, and 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the curve (AUC) adjusted by baseline in virus titer - Defined as AUC of change from baseline in virus titer. The AUC is calculated using the trapezoidal method.</outcome>
      <timepoint>Day 1 to Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the curve (AUC) adjusted by baseline in viral RNA load - Defined as AUC of change from baseline in viral RNA load. The AUC is calculated using the trapezoidal method.</outcome>
      <timepoint>Day 1 to Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to cessation of viral shedding - Defined as the time between the initiation of the study treatment and first time when the virus titer/RT-PCR is less than the lower limit of quantification</outcome>
      <timepoint>From Day 1 to Day 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants whose symptoms have been alleviated at each time point</outcome>
      <timepoint>Days 2-9, morning and evening, and days 10-14, evenings</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to alleviation of symptoms - Time to alleviation of symptoms is defined as the time between the initiation of the study treatment and the alleviation of influenza symptoms. The alleviation of influenza symptoms is defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient.</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to improvement in the 4 systemic symptoms - Defined as the time between the initiation of the study treatment and the improvement in the 4 systemic symptoms symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue).</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to improvement in the 3 respiratory symptoms - Defined as the time between the initiation of the study treatment and the improvement in the 3 respiratory symptoms (cough, sore throat, and nasal congestion).</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to resolution of fever - Defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever is defined as the time when the patient's self-measured temperature becomes less than 37ºC.</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants reporting normal temperature at each time point - Defined as the percentage of patients whose self-measured temperature drops to less than 37ºC after the initiation of the study treatment.</outcome>
      <timepoint>Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body temperature at each time point</outcome>
      <timepoint>Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to improvement of each influenza symptom - Defined as the time between the initiation of the study treatment and the alleviation of each influenza symptom.</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to return to preinfluenza health status - Patients will be asked to record their preinfluenza health status (for someone your age and your health condition). Return to preinfluenza health status is defined as time from the initiation of the study treatment to time to return to preinfluenza health status.</outcome>
      <timepoint>Day 1 pretreatment up to Day 14</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants requiring systemic antibiotics for infections secondary to influenza infection</outcome>
      <timepoint>Day 2 to Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with influenza-related complications - Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.</outcome>
      <timepoint>Day 1 to Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with adverse events - The frequency of AEs in patients with influenza after S-033188 , after oseltamivir, and after placebo.</outcome>
      <timepoint>Day 1 to Day 22 plus or minus 3 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients or their legal guardians who provide written informed consent to participate
             in the study on a voluntary basis. For adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements.

          2. Male or female patients = 12 years at the time of signing the informed consent/assent
             form.

          3. Patients with a duration of influenza symptoms confirmed by all of the following:

               1. Fever = 38ºC (axillary) during the predose examinations or within the 4 hours
                  prior if antipyretics were taken

               2. At least 1 each of the following general and respiratory symptoms associated with
                  influenza is present with a severity of moderate or greater:

             i. General symptoms (headache, feverishness or chills, muscle or joint pain, or
             fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least 1 new general or respiratory symptom

          5. If a women of childbearing potential, agrees to use a highly effective method of
             contraception for 3 months after the first dose of study drug

          6. Patients will be considered at high risk* of influenza complications due to the
             presence of at least 1 of the following inclusion criteria:

               1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or
                  cystic fibrosis)

               2. Endocrine disorders (including diabetes mellitus)

               3. Residents of long-term care facilities (eg, nursing homes)

               4. Compromised immune system (including patients receiving corticosteroids not
                  exceeding 20 mg of prednisolone or equivalent, and patients being treated for
                  human immunodeficiency virus (HIV) infection with a CD4 count &gt; 350 cells/mm³
                  within the last 6 months)

               5. Neurological and neurodevelopmental disorders (including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, muscular dystrophy, or spinal cord injury)

               6. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms

               7. Adults aged = 65 years

               8. American Indians and Alaskan Natives

               9. Blood disorders (such as sickle cell disease)

              10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial
                  disorders)

              11. Morbid obesity (body mass index = 40)

              12. Women who are within 2 weeks postpartum and are not breastfeeding</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients with known allergy to oseltamivir (Tamiflu®).

          3. Patients unable to swallow tablets or capsules.

          4. Patients who have previously received S-033188.

          5. Patients weighing = 40 kg.

          6. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the
             predose examinations. The following female patients who have documentation of either a
             or b below do not need to undergo a pregnancy test at the predose examinations:

               1. Postmenopausal women (defined as cessation of regular menstrual periods for 2
                  years or more and confirmed by a follicle-stimulating hormone test)

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          8. Patients with concurrent infections at the predose examinations requiring systemic
             antimicrobial therapy.

          9. Patients with liver disease associated with hepatic impairment.

         10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).

         11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below
             350 cells/mm3 in the last 6 months.

         12. Patients with immunosuppression following organ or bone marrow transplants.

         13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic
             corticosteroids.

         14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir or amantadine within 30 days prior to the predose
             examinations.

         15. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         16. Patients with known creatinine clearance = 60 mL/min.

         17. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2157</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW</recruitmentstate>
    <hospital>Shionogi Research Site - Bruce</hospital>
    <hospital>Shionogi Research Site - Bathurst</hospital>
    <hospital>Shionogi Research Site - Darlinghurst</hospital>
    <hospital>Shionogi Research Site - Forbes</hospital>
    <hospital>Shionogi Research Site - Kanwal</hospital>
    <hospital>Shionogi Research Site - North Sydney</hospital>
    <hospital>Shionogi Research Site - Tumbi Umbi</hospital>
    <postcode>2617 - Bruce</postcode>
    <postcode>2795 - Bathurst</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2871 - Forbes</postcode>
    <postcode>2259 - Kanwal</postcode>
    <postcode>2060 - North Sydney</postcode>
    <postcode>2261 - Tumbi Umbi</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukui</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kagoshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Oita</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okinawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shiga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Chungcheongnam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gangwon-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Balvi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Jelgava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Madliena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Salaspils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Saldus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Mpumalanga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Ilan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>New Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cornwall</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Shionogi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the efficacy of a single, oral dose of
      S-033188 compared with placebo by measuring the time to improvement of influenza symptoms in
      patients with influenza presenting within 48 hours of symptom onset.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02949011</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Shionogi Clinical Trials Administrator Clinical Support Help Line</name>
      <address>Shionogi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Shionogi Clinical Trials Administrator Clinical Support Help Line</name>
      <address />
      <phone>800-849-9707</phone>
      <fax />
      <email>Shionogiclintrials-admin@shionogi.co.jp</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>